ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

317
Analysis
Health CareChina
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
19 Dec 2024 10:58

Henlius (2696 HK): This Should Trade Tighter. Get Involved

A 3.1% gross spread with expected payment around mid-Feb is okay. I'd pay up to HK$24.10/share for a 15% annualised spread. This is done. Get...

Logo
497 Views
Share
17 Dec 2024 00:51

Henlius (2696 HK): NDRC Approval Should Calm Nerves

Fosun Pharma has satisfied the precondition related to its Henlius’ HK$24.60 offer. The composite document will be despatched by 23 January. Key...

Logo
825 Views
Share
bullishESR Group
16 Dec 2024 01:34

Merger Arb Mondays (16 Dec) - ESR, CPMC, Fosun Tourism, Seven & I, Fuji Soft, NEC Networks

This week, the highest gross spreads are Arcadium Lithium (13.8%), Seven & I (11.6%), Insignia (10.8%), Henlius (10.8%), Get Nice (10.3%), ESR...

Logo
472 Views
Share
bullishCPMC Holdings
15 Dec 2024 07:00

CPMC (906 HK): Not A Shadow Of Doubt (!) As Pre-Cons Fulfilled

Awesome news to see the pre-cons satisfied. Expect Canvest and Henlius to also narrow into terms. If this turns unco on the first closing date,...

Logo
485 Views
Share
bullishFuji Soft Inc
15 Dec 2024 06:30

(Mostly) Asia-Pac M&A: Insignia, Fosun Tourism, GJS/Haitong, Fuji Soft, Dexus Property

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
395 Views
Share
x